X4 Pharmaceuticals (XFOR) Non-Current Assets (2017 - 2025)

X4 Pharmaceuticals has reported Non-Current Assets for 9 years, with the latest figure at $28.9 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets fell 15.72% year-over-year to $28.9 million; the trailing twelve-month figure through Dec 2025 stood at $126.2 million (down 2.57% YoY), and the FY2025 full-year result was $28.9 million, down 15.72% from the prior year.
• Non-Current Assets for Q4 2025 stood at $28.9 million, down from $30.8 million in the prior quarter.
• The five-year high for Non-Current Assets was $41.1 million in Q1 2021, with the low at $24.8 million in Q1 2024.
• Historically, Non-Current Assets has averaged $31.0 million across 5 years, with a median of $29.1 million in 2021.
• Annual changes were most pronounced in 2022 — Non-Current Assets plunged 30.46% — and 2024, when it soared 38.44%.
• X4 Pharmaceuticals' Non-Current Assets stood at $29.3 million in 2021, then fell by 8.15% to $26.9 million in 2022, then declined by 6.42% to $25.2 million in 2023, then surged by 36.1% to $34.3 million in 2024, then fell by 15.72% to $28.9 million in 2025.
• The last three Non-Current Assets figures came in at $28.9 million (Q4 2025), $30.8 million (Q3 2025), and $32.2 million (Q2 2025), per Business Quant data.